Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing
This WES-AI-ML framework provides mutation-guided therapies for BC-CML, enabling real-time stratification and Food and Drug Administration-approved drug repurposing. While this exploratory study is limited by its small sample size (<i>n</i> = 7), it establishes a methodological framework for precision oncology stratification that warrants validation in larger, multi-center cohorts.
Authors
- Abdulaziz Siyal
- Giuseppe Saglio (ORCID: https://orcid.org/0000-0002-1046-3514)
- Aamer Aleem (ORCID: https://orcid.org/0000-0001-5774-0358)
- Nawaf Alanazi
- Sameerah Shaheen (ORCID: https://orcid.org/0000-0003-0646-1847)
- Hassan H Almasoudi
- Masood A. Shammas (ORCID: https://orcid.org/0000-0002-8932-6829)
- Sultan Alqahtani (ORCID: https://orcid.org/0000-0001-9050-7988)
- Sarah AlMukhaylid (ORCID: https://orcid.org/0009-0000-0646-367X)
- Zafar Iqbal (ORCID: https://orcid.org/0000-0001-5863-9518)
- Abrar Hussain (ORCID: https://orcid.org/0000-0003-0335-3103)
- Yaqob Samir Taleb
- Abdulkareem Al-Garni
- Rizwan Naeem
- Deema Alroweilly
- Nada Alkhamis
Institutions
- Najran University (SA)
- University of Turin (IT)
Publication Details
- Journal
- World Journal of Clinical Oncology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.5306/wjco.v16.i11.111983
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77